Show simple item record

Files in this item


Item metadata

dc.contributor.authorHroch, Lukas
dc.contributor.authorGuest, Patrick
dc.contributor.authorBenek, Ondrej
dc.contributor.authorSoukup, Ondrej
dc.contributor.authorJanockova, Jana
dc.contributor.authorDolezal, Rafael
dc.contributor.authorKuca, Kamil
dc.contributor.authorAitken, Laura
dc.contributor.authorSmith, Terry K.
dc.contributor.authorGunn-Moore, Frank
dc.contributor.authorZala, Dominykas
dc.contributor.authorRamsay, Rona R.
dc.contributor.authorMusilek, Kamil
dc.identifier.citationHroch , L , Guest , P , Benek , O , Soukup , O , Janockova , J , Dolezal , R , Kuca , K , Aitken , L , Smith , T K , Gunn-Moore , F , Zala , D , Ramsay , R R & Musilek , K 2017 , ' Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer’s disease treatment ' , Bioorganic & Medicinal Chemistry , vol. 25 , no. 3 , pp. 1143-1152 .
dc.identifier.otherPURE: 248219434
dc.identifier.otherPURE UUID: 5e51b928-c712-4e9e-b7e8-8d62bd7d0834
dc.identifier.otherScopus: 85010904474
dc.identifier.otherORCID: /0000-0003-1535-4904/work/34907339
dc.identifier.otherORCID: /0000-0003-3422-3387/work/34730411
dc.identifier.otherORCID: /0000-0001-7259-4491/work/31318393
dc.identifier.otherWOS: 000394201900031
dc.descriptionThis work was supported by the Ministry of Health of the Czech Republic (no. NV15-28967A), the Charles University in Prague (SVV 260 291), COST Action CM1103 (STSM 15879 and 17487) and CA15135, University of Hradec Kralove (Faculty of Informatics and Management, project Excellence 2015), University of St Andrews (undergraduate project funding to D.Z.), Biotechnology and Biological Sciences Research Council (BBSRC; no. BB/J01446X/1), the Alzheimer’s Society and the Barcopel Foundation.en
dc.description.abstractAlzheimer’s disease (AD) is a neurodegenerative disorder associated with an excessive accumulation of amyloid-beta peptide (Aβ). Based on the multifactorial nature of AD, preparation of multi-target-directed ligands presents a viable option to address more pathological events at one time. A novel class of asymmetrical disubstituted indolyl thioureas have been designed and synthesized to interact with monoamine oxidase (MAO) and/or amyloid-binding alcohol dehydrogenase (ABAD). The design combines the features of known MAO inhibitors scaffolds (e.g. rasagiline or ladostigil) and a frentizole moiety with potential to interact with ABAD. Evaluation against MAO identified several compounds that inhibited in the low to moderate micromolar range. The most promising compound ( 19 ) inhibited human MAO-A and MAOB with IC50 values of 6.34 μM and 0.30 μM, respectively. ABAD activity evaluation did not show any highly potent compound, but the compound series allowed identification of structural features to assist the future development of ABAD inhibitors. Finally, several of the compounds were found to be potent inhibitors of horseradish peroxidase (HRP), preventing the use of the Amplex™ Red assay to detect hydrogen peroxide produced by MAO, highlighting the need for serious precautions when using an enzyme-coupled assay.
dc.relation.ispartofBioorganic & Medicinal Chemistryen
dc.rights© 2016, Elsevier. This work has been made available online in accordance with the publisher’s policies. This is the author created, accepted version manuscript following peer review and may differ slightly from the final published version. The final published version of this work is available at /
dc.subjectAlzheimer's disease (AD)en
dc.subjectMonoamine oxidase (MAO)en
dc.subjectAmyloid-beta peptide (Aβ)en
dc.subjectMitochondrial amyloid-binding alcohol dehydrogenase (ABAD)en
dc.subject17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10)en
dc.subjectHorseradish peroxidase (HRP)en
dc.subjectQD Chemistryen
dc.subjectQH301 Biologyen
dc.subjectRC0321 Neuroscience. Biological psychiatry. Neuropsychiatryen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.titleSynthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer’s disease treatmenten
dc.typeJournal articleen
dc.contributor.institutionUniversity of St Andrews. School of Biologyen
dc.contributor.institutionUniversity of St Andrews. Biomedical Sciences Research Complexen
dc.contributor.institutionUniversity of St Andrews. Institute of Behavioural and Neural Sciencesen
dc.description.statusPeer revieweden

This item appears in the following Collection(s)

Show simple item record